Results 201 to 210 of about 45,133,671 (398)

Modified Star Excursion Balance Test Performance in Individuals With Chronic Ankle Instability: A Participant-Level Analysis. [PDF]

J Foot Ankle Res
Forsyth L, Simpson J, Pourkazemi F, Torp DM, Burcal C, Koldenhoven RM, Donovan L, Jaffri A, Al Adal S, Mitchell A, Childs CR.   +10 more
europepmc   +1 more source

University of Glasgow : Freshwater Biological Laboratory and Insect Field Station [PDF]

, 1947

openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

volume 13, no. 1 (Spring 2008) [PDF]

, 2008
Office of University Advancement, Bryant University
core   +1 more source

Evaluation of GABAergic and Glutamatergic Levels in the Dorsal Anterior Cingulate Cortex of Patients With Bipolar Disorder: A Cross-Sectional ¹H-MRS Study. [PDF]

Neuropsychopharmacol Rep
Moriyama S, Noda Y, Honda S, Edden RAE, Takahashi K, Saito K, Taniguchi K, Wada M, Tsugawa S, Tobari Y, Huh S, Nakane Y, Homma S, Matsui M, Koike S, Mimura M, Uchida H, Nakajima S.   +17 more
europepmc   +1 more source

University and Educational Intelligence [PDF]

, 1919

openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

volume 4, no. 3 (Summer 2000) [PDF]

, 2000
Office of University Advancement, Bryant University
core   +1 more source

Correction: GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy. [PDF]

Mol Psychiatry
Lemke JR, Eoli A, Krey I, Popp B, Strehlow V, Wittekind DA, Vuorinen AL, Aldhalaan HM, Baer S, de Saint Martin A, Hammer TB, Herman I, Hornemann F, Ingebrigtsen T, Lederer D, Lesca G, Marafie D, Mathot M, Rosenfeld JA, Møller RS, Schelhaas HJ, Stillman C, Orsini A, Patel AD, Piard J, Veggiotti P, Vlaskamp DRM, Weckhuysen S, Traynelis SF, Benke TA, Heyne HO, Syrbe S.   +31 more
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source